# EDGAR Filing Document

**Accession Number:** 0001365831
**File Stem:** 0001477932-26-001162
**Filing Date:** 2026-3
**Character Count:** 7038
**Document Hash:** 2dbd0d2a367fe076e661fbbd26f3fe30
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001477932-26-001162.hdr.sgml**: 20260304

**ACCESSION NUMBER**: 0001477932-26-001162

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260225

**FILED AS OF DATE**: 20260304

**DATE AS OF CHANGE**: 20260304

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** JAMES MICHAEL C
- **CENTRAL INDEX KEY:** 0001365831

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-22179
- **FILM NUMBER:** 26720929

**MAIL ADDRESS:**
- **STREET 1:** 283 COUNTY ROAD 519
- **CITY:** BELVIDERE
- **STATE:** NJ
- **ZIP:** 07823
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GUIDED THERAPEUTICS INC
- **CENTRAL INDEX KEY:** 0000924515
- **STANDARD INDUSTRIAL CLASSIFICATION:** ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 582029543
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 5835 PEACHTREE CORNERS EAST
- **STREET 2:** SUITE B
- **CITY:** PEACHTREE CORNERS
- **STATE:** GA
- **ZIP:** 30092
- **BUSINESS PHONE:** 7702428723

**MAIL ADDRESS:**
- **STREET 1:** 5835 PEACHTREE CORNERS EAST
- **STREET 2:** SUITE B
- **CITY:** PEACHTREE CORNERS
- **STATE:** GA
- **ZIP:** 30092

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SPECTRX INC
- **DATE OF NAME CHANGE:** 19970226

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>JAMES MICHAEL C<br><sub>(Last) (First) (Middle)</sub><br>5835 PEACHTREE CORNERS EAST<br>SUITE B<br><sub>(Street)</sub><br>PEACHTREE CORNERS, GA 30092<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-02-25-05:00 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>GUIDED THERAPEUTICS INC [ GTHP ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2026-02-25-05:00 |  | X |  | 100000 | A | <sup>(1)</sup> | 653495 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Warrants | $0.50 | 2026-02-25-05:00 |  | J<sup>(1)</sup> |  |  | 100000 | 2022-09-01-05:00 | 2026-09-01-05:00 | Common Stock | 100000 | <sup>(1)</sup> | 0 | D |  |
| Warrants | $0.50 | 2026-02-25-05:00 |  | J<sup>(1)</sup> |  | 100000 |  | 2026-02-25-05:00 | 2027-09-01-05:00 | Common Stock | 100000 | <sup>(1)</sup> | 100000 | D |  |
| Warrants | $0.65 | 2026-02-25-05:00 |  | J<sup>(1)</sup> |  |  | 100000 | 2022-09-01-05:00 | 2026-09-01-05:00 | Common Stock | 100000 | <sup>(1)</sup> | 0 | D |  |
| Warrants | $0.25 | 2026-02-25-05:00 |  | J<sup>(1)</sup> |  | 100000 |  | 2026-02-25-05:00 | 2026-02-25-05:00 | Common Stock | 100000 | <sup>(1)</sup> | 152778 | D |  |
| Warrants | $0.25 | 2026-02-25-05:00 |  | X |  |  | 100000 | 2026-02-25-05:00 | 2026-02-25-05:00 | Common Stock | 100000 | <sup>(1)</sup> | 52778 | D |  |

---

### Footnotes:

(1) During February 2026, Mr. James signed an exchange agreement to exchange 100,000 warrants to purchase shares of common stock with an exercise price of $0.65 for 100,000 warrants to purchase shares of common stock for an exercise price of $0.25. The newly exchanged warrants were subsequently exercised upon payment of $25,000. Moreover, as part of the exchange agreement, the expiration date of 4-year 100,000 warrants to purchase shares of common stock with exercise price of $0.50 was extended for an additional year, until September 1, 2027.

**Signature:** /s/ Michael C James  
**Date:** 2026-03-04-05:00

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**